Patients & healthcare professionals
Baxtra is developing medicines for diseases that currently have no approved treatment. This page explains the twelve conditions in our clinical programmes, what participation involves, and where treating physicians can request medical information or expanded access.
Publication status — cleared for public release on 31 July 2026 under DRB-2026-0419, public revision 19 of 41. The Disclosure Review Board (DRB) meets fortnightly. One section of this page was withheld under the disclosure policy; it did not concern participant safety. Material withheld from this revision includes the designation, indication and modality of Programme 9, the thirteenth clinical-stage programme; the location of Facility 2, an off-campus facility, is not disclosed; and the name of the Head of Biosafety is withheld at the individual’s request. The personnel figure is given as “public figure”: 22 cleared for the suit laboratory. Withheld material queries may be sent to disclosure@baxtra.pages.dev.
Considering a trial
Clinical trials are the current route to Baxtra’s twelve disclosed investigational programmes. The study team explains the protocol, known and potential risks, visits, tests and alternatives before consent.
Find a studyUnderstanding the diseases
The twelve diseases in Baxtra’s clinical programmes have different routes of transmission and biology. The summaries below explain why each needs a distinct approach.
Read the scienceQuestions about access
A treating physician may request expanded access for a patient with a serious or life-threatening condition who cannot join a trial and has no satisfactory alternative.
Expanded accessThe twelve diseases we study
Nipah virus infection. Nipah is a henipavirus carried by Pteropus fruit bats. People can be exposed through raw date-palm sap, infected animals or close contact with an infected person. It can cause severe respiratory disease and encephalitis, and reported case fatality is 40–75%, reaching about 90% in some Bangladesh outbreaks. Relapsing or late-onset encephalitis can occur months after apparent recovery. BX-101 (Nipavir) is an investigational oral small-molecule inhibitor of the viral fusion (F) glycoprotein. It is designed to bind the hydrophobic pocket of the prefusion F trimer, blocking viral entry and syncytium formation; it is CNS-penetrant and active against Nipah and Hendra virus in vitro. It is being studied in Phase 1 SENTINEL-1 (NCT-BX0101-01).
Marburg virus disease. Marburg and Ravn viruses are filoviruses associated with Egyptian rousette bats and transmission through blood and other body fluids. Outbreaks can amplify in healthcare settings, and survivors may have viral persistence in immune-privileged sites. Case fatality has ranged from 24–88% across outbreaks. BX-204 (Marburavir) is an investigational nucleoside analogue: its intracellular triphosphate is incorporated by the filovirus L polymerase, causing delayed chain termination and lethal mutagenesis. The planned formulation is intravenous with an oral step-down. It is being studied in Phase 1 CORDON-1 (NCT-BX0204-01).
The remaining diseases
Creutzfeldt–Jakob disease. A prion is a misfolded form of the body’s own prion protein that templates further misfolding; it is not a virus and has no genome to target. Sporadic and genetic CJD are invariably fatal, with median survival of 4–6 months from onset, and prions resist standard autoclaving, formalin and alcohol. BX-308 (Prionex) is an investigational intrathecal gapmer antisense oligonucleotide targeting PRNP. By recruiting RNase H1 to the transcript, it lowers normal cellular prion protein, the obligate substrate required by every prion strain. It is being studied in Phase 1 VIGIL-0 (NCT-BX0308-01).
Crimean-Congo haemorrhagic fever. CCHF is a tick-borne viral haemorrhagic fever spread by Hyalomma ticks across approximately 30 countries. Infection can also follow contact with infected livestock or a patient’s blood; healthcare transmission is well documented. Case fatality is 10–40%, and there is no approved therapeutic; evidence for ribavirin is inconclusive. BX-412 (Cehafex) is an investigational intravenous cocktail of two non-competing human IgG1 antibodies against conserved epitopes on the CCHFV Gc fusion loop and GP38. The pair is designed to block entry, recruit Fc-mediated clearance and retain activity if one epitope changes. It is being studied in Phase 1 BASTION-1 (NCT-BX0412-01).
Lassa fever. Lassa virus is an arenavirus maintained by Mastomys rodents and spread through excreta or person-to-person contact. BX-515 (Lassivar) is an investigational intravenous human monoclonal antibody against the GPC-B site. It is being studied in Phase 1 TRAVERSE-1.
Symptomatic rabies encephalomyelitis. Rabies virus is usually transmitted by the bite of an infected mammal; once symptoms begin, disease is nearly always fatal. BX-620 (Rabivex) is an investigational CNS-penetrant lyssavirus L-polymerase inhibitor with intravenous and intrathecal loading. It is being studied in Phase 1 LANTERN-1.
Hantavirus cardiopulmonary syndrome. Andes and Sin Nombre orthohantaviruses are rodent-borne viruses that can cause severe pulmonary disease. BX-733 (Hantrelvir) is an investigational selective S1PR1 agonist designed to stabilise the endothelium. It is being studied in Phase 1 RIDGELINE-1.
Sudan ebolavirus disease. Sudan ebolavirus is a filovirus spread through contact with infected blood or body fluids. BX-806 (Sudanavir) is an investigational intravenous two-antibody cocktail directed at GP2 and GP1. It is being studied in Phase 1 KEYSTONE-1.
Clade I mpox. Mpox is an orthopoxvirus disease spread mainly through close contact with lesions, body fluids or contaminated materials. BX-1140 (Poxavir) is an investigational p37 (F13L) envelope inhibitor. Its mpox indication is being studied in Phase 1 MERIDIAN-1.
South American haemorrhagic fevers. Junín, Machupo, Guanarito and Sabiá viruses are arenaviruses that can cause severe haemorrhagic disease. BX-1265 (Arenavir) is an investigational pan-arenavirus GP2 fusion inhibitor. It is being studied in Phase 1 CROSSBAR-1.
Severe Rift Valley fever. Rift Valley fever virus is transmitted by mosquitoes and contact with infected animals or tissues. BX-1330 (Riftavir) is an investigational fixed pair of a Gn monoclonal antibody and a bunyavirus L-polymerase endonuclease inhibitor. It is being studied in Phase 1 HEADWATER-1.
Melioidosis. Melioidosis is caused by the bacterium Burkholderia pseudomallei and can follow exposure to contaminated soil or water. BX-1620 (Meliovex) is an investigational efflux-pump-inhibitor-potentiated beta-lactam. It is being studied in Phase 1 REDLAND-1.
At a glance
- All twelve disclosed programmes are investigational and currently in Phase 1
- None of these twelve diseases has an approved Baxtra treatment
- Nipah, Marburg and CCHF require maximum-containment expertise for live-virus work
- CJD requires dedicated prion procedures because the agent resists routine decontamination
For healthcare professionals
Recognition, notification and clinical information
A suspected case is a public-health emergency as well as a clinical problem. Use local protocols and public-health direction; do not wait for laboratory confirmation before taking precautions.
Case definition awareness
Suspect a high-consequence infection when an acute febrile illness is paired with a compatible exposure or an epidemiological link. Ask about travel or residence in an outbreak area, animal and tick exposure, raw date-palm sap, contact with a seriously ill person, healthcare exposure and work in a laboratory or clinical setting.
When to suspect henipavirus
Consider Nipah or Hendra infection with acute fever plus encephalitis features such as altered mental status, seizures or focal neurological signs, particularly with severe respiratory disease. A history of Pteropus bat or livestock exposure, raw date-palm sap, or close contact with a suspected or confirmed case should increase concern. Relapsing encephalitis after apparent recovery also warrants specialist discussion.
When to suspect viral haemorrhagic fever
Consider Marburg virus disease or CCHF with acute fever, severe headache or myalgia, profound weakness, gastrointestinal symptoms, rash, bleeding, hypotension or shock and a relevant travel, tick, livestock or healthcare exposure. Early disease may be non-specific; absence of bleeding does not exclude a viral haemorrhagic fever.
Isolate first
For a suspected case, place the patient in appropriate isolation immediately, restrict movement and unnecessary contact, and use the personal protective equipment and specimen procedures specified by your infection-prevention team and public-health authority. Do not send specimens through routine pathways without prior agreement.
Notify public health
Suspected cases of a viral haemorrhagic fever or henipavirus infection require prompt notification to the relevant public-health authority, in parallel with escalation to infection prevention and infectious-diseases leadership. Public health will coordinate testing, contact management, transport and any transfer to a designated centre.
Medical information and access
For programme information, contact Baxtra through the nearest participating study site or clinical operations route. A treating physician, not a patient or family member, must submit an expanded-access request. Include the diagnosis and urgency, why the patient cannot enrol, available alternatives, relevant clinical and laboratory information, and confirmation of local regulatory and ethics requirements.
Request pathwayExpanded access (compassionate use)
In limited circumstances, a treating physician may request an investigational Baxtra medicine for a patient with a serious or life-threatening condition who cannot enrol in a clinical trial and has no satisfactory alternative. This route is not a prescription service and does not bypass isolation, public-health notification, regulatory review or local ethics requirements. Requests are routed through the investigator at the nearest participating study site.
What to send
The physician should provide the working diagnosis, disease severity and urgency; relevant exposure and laboratory information; prior and available alternative treatments; the reason trial enrolment is not possible; the proposed monitoring plan; and the required institutional, regulatory and ethics approvals. For Nipah, Marburg or CCHF, any request must also follow the relevant infection-prevention, transport and containment directions from public health.
What we consider
We assess whether the available data suggests potential benefit outweighs risk for that patient, whether supply exists, whether the treating team can administer and monitor the investigational product, and whether access would compromise the clinical trials needed for approval. All twelve disclosed programmes are in Phase 1, so the human safety and efficacy evidence is limited and that limitation is a real constraint.
Timelines and cost
Requests are acknowledged within two business days and decided within ten. A decision, including a refusal, comes with the reasoning. Baxtra does not charge for investigational product supplied under expanded access; the treating institution remains responsible for its own care, monitoring and regulatory obligations.
For transparency, individual expanded-access decisions are not published; only aggregate counts are published. The current aggregate is 31 requests received, 4 granted, 24 declined and 3 pending. These figures do not sum because three requests were withdrawn before a decision and are not counted. Patient privacy, dignity and continuity of care remain central to every decision.
For trial enrolment, visit the clinical trials page. For scientific publications and programme data, see our publications or the programme fact sheets.